← Leaderboards
Rosemarie M Booze
University Of Kentucky
$13,099,681
Attributed
$18,044,467
Total exposure
10
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,044,467 · 10
By mechanism
R01$17,104,780 · 8
K02$538,889 · 1
R21$400,798 · 1
Top collaborators
- Charles F. Mactutus23 shared
- Norma Frizzell2 shared
- Michael Shtutman2 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Kurt Francis Hauser$27,368,955
- Charles F. Mactutus$6,378,382
- Avindra Nath$17,882,997
- Joseph R Berger$2,809,271
- Michal J. Toborek$37,025,871
Others in their field
Top investigators on “Female”
- Philip J Disaia · University Of California Irvine$140,003,514
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$103,542,269
- Wafaa M. El-Sadr · Columbia University Health Sciences$102,372,214
- Myron S Cohen · Family Health International$101,800,876
- Walter John Curran · Thomas Jefferson University$57,608,324
- Gregory S Boebinger · Florida State University$55,673,680
Research focus
FemaleIn VivoProteinsNeurocognitiveFunctional DisorderRattusHiv-1Nucleus AccumbensCocaineNeuronsChronicImpairmentBrainAntiretroviral TherapyEstrogensHiv InfectionsInfectionProgramsLongitudinal DesignDopamineMediatingImpaired CognitionSynapsesVertebral Column
Grant awards (55)
Executive Function Impairments in HAND and Aging$587,739
R01 · FY2025 · AG
Microglial modulation of neurocircuits in HIV/cocaine comorbidity$653,642
R01 · FY2024 · DA · contact PI
Executive Function Impairments in HAND and Aging$573,415
R01 · FY2024 · AG
Targeting Immunometabolism: a novel role for itaconate in the treatment of HIV-associated neurocognitive disorder and cocaine use disorder$181,708
R21 · FY2024 · DA
Microglial modulation of neurocircuits in HIV/cocaine comorbidity$669,734
R01 · FY2023 · DA · contact PI
Targeting Immunometabolism: a novel role for itaconate in the treatment of HIV-associated neurocognitive disorder and cocaine use disorder$219,090
R21 · FY2023 · DA
HIV/COCAINE NEUROTOXICITY IN FEMALES$578,365
R01 · FY2021 · DA · contact PI
Neurobiological Mechanisms of Apathy in HAND$366,250
R01 · FY2021 · NS
HIV/COCAINE NEUROTOXICITY IN FEMALES$581,031
R01 · FY2020 · DA · contact PI
Neurobiological Mechanisms of Apathy in HAND$366,250
R01 · FY2020 · NS
Progression of Attentional and Executive Function Deficits in HAND$366,250
R01 · FY2020 · MH
HIV/COCAINE NEUROTOXICITY IN FEMALES$583,662
R01 · FY2019 · DA · contact PI
Neurobiological Mechanisms of Apathy in HAND$366,250
R01 · FY2019 · NS
Progression of Attentional and Executive Function Deficits in HAND$366,250
R01 · FY2019 · MH
HIV/COCAINE NEUROTOXICITY IN FEMALES$586,217
R01 · FY2018 · DA · contact PI
Neurobiological Mechanisms of Apathy in HAND$366,250
R01 · FY2018 · NS
Progression of Attentional and Executive Function Deficits in HAND$366,250
R01 · FY2018 · MH
HIV/COCAINE NEUROTOXICITY IN FEMALES$600,321
R01 · FY2017 · DA · contact PI
Neurobiological Mechanisms of Apathy in HAND$366,250
R01 · FY2017 · NS
Progression of Attentional and Executive Function Deficits in HAND$366,250
R01 · FY2017 · MH
Progression of Attentional and Executive Function Deficits in HAND$366,250
R01 · FY2016 · MH
Maternal HIV: Developmental Neurotoxicity$297,866
R01 · FY2016 · HD
HIV/Cocaine Neurotoxicity in Females$357,062
R01 · FY2015 · DA · contact PI
Maternal HIV: Developmental Neurotoxicity$293,352
R01 · FY2015 · HD
Maternal HIV: Developmental Neurotoxicity - Administrative Supplement$131,850
R01 · FY2015 · HD
HIV/Cocaine Neurotoxicity in Females$362,500
R01 · FY2014 · DA · contact PI
Maternal HIV: Developmental Neurotoxicity$292,450
R01 · FY2014 · HD
HIV/Cocaine Neurotoxicity in Females$348,000
R01 · FY2013 · DA · contact PI
Maternal HIV: Developmental Neurotoxicity$285,531
R01 · FY2013 · HD
HIV/Cocaine Neurotoxicity in Females$362,500
R01 · FY2012 · DA · contact PI
Maternal HIV: Developmental Neurotoxicity$300,875
R01 · FY2012 · HD
HIV/Cocaine Neurotoxicity in Females$362,500
R01 · FY2011 · DA · contact PI
HIV/Cocaine Neurotoxicity in Females$296,523
R01 · FY2009 · DA · contact PI
HIV/Cocaine Neurotoxicity in Females$334,755
R01 · FY2008 · DA · contact PI
HIV/Cocaine Neurotoxicity in Females$341,587
R01 · FY2007 · DA · contact PI
HIV/Cocaine Neurotoxicity in Females$311,611
R01 · FY2006 · DA · contact PI
Neurodevelopmental Basis(es) of Nicotine Sensitization$284,162
R01 · FY2006 · DA · contact PI
HIV/Cocaine Neurotoxicity in Females$40,178
R01 · FY2006 · DA · contact PI
HIV/Cocaine Neurotoxicity in Females$329,871
R01 · FY2005 · DA
Neurodevelopmental Basis(es) of Nicotine Sensitization$291,000
R01 · FY2005 · DA
HIV/Cocaine Neurotoxicity in Females$115,668
K02 · FY2005 · DA
Neurodevelopmental Basis(es) of Nicotine Sensitization$291,000
R01 · FY2004 · DA
HIV/Cocaine Neurotoxicity in Females$115,668
K02 · FY2004 · DA
HIV/COCAINE NEUROTOXICITY IN FEMALES$341,848
R01 · FY2003 · DA
Neurodevelopmental Basis(es) of Nicotine Sensitization$291,000
R01 · FY2003 · DA
HIV/Cocaine Neurotoxicity in Females$115,668
K02 · FY2003 · DA
Neurodevelopmental Basis(es) of Nicotine Sensitization$303,750
R01 · FY2002 · DA
HIV/COCAINE NEUROTOXICITY IN FEMALES$157,213
R01 · FY2002 · DA
HIV/COCAINE NEUROTOXICITY IN FEMALES$132,387
R01 · FY2002 · DA
HIV/Cocaine Neurotoxicity in Females$115,668
K02 · FY2002 · DA
HIV/COCAINE NEUROTOXICITY IN FEMALES$32,513
R01 · FY2002 · DA
HIV/COCAINE NEUROTOXICITY IN FEMALES$289,700
R01 · FY2001 · DA
HIV/Cocaine Neurotoxicity in Females$76,217
K02 · FY2001 · DA
HIV/COCAINE NEUROTOXICITY IN FEMALES$326,250
R01 · FY2000 · DA
GENDER DIFFERENCES IN COCAINE RESPONSIVENESS$238,320
R01 · FY2000 · DA